|1.||Peterson, Matt A: 1 article (05/2009)|
|2.||Balzarini, Jan: 1 article (05/2009)|
|3.||Yang, Hong: 1 article (05/2009)|
|4.||De Clercq, Erik: 1 article (05/2009)|
|5.||Miranda, Karl: 1 article (05/2009)|
|6.||Robins, Morris J: 1 article (05/2009)|
|7.||Savickiene, J: 1 article (10/2003)|
|8.||Gineitis, A: 1 article (10/2003)|
01/01/1980 - "Phase I study of 3-deazauridine in the treatment of adults with solid tumors."
05/14/2009 - "The cytostatic activity of 3-fluoro-3-deazauridine (CC(50) = 4.4-9.6 microM) in three cancer cell lines paralleled that of 3-deazauridine, whereas no significant inhibitory activity was observed with a variety of virus-infected cell cultures."
10/01/1979 - "The antitumor agent 3-deazauridine (DAU) was administered rapidly to four patients before surgical removal of intracerebral tumor. "
10/01/1979 - "Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid."
01/01/1980 - "A phase I trial of the uridine analog 3-deazauridine was undertaken in 44 adults with solid tumors. "
05/01/1981 - "Phase I--II study of 3-deazauridine in adults with acute leukemia."
01/01/1974 - "Inhibition of gross leukemia virus-induced plaque formation in XC cells by 3-deazauridine."
03/01/1981 - "In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia."
01/01/1991 - "Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model."
05/01/1981 - "3-Deazauridine, a uridine analog, was administered to 36 patients with acute leukemia by both intermittent and continuous iv infusion at doses ranging from 400 to 6000 mg/m2/day x 5, repeated at 1--3-week intervals. "
06/01/1978 - "3-Deazauridine enhanced the anabolism of ara-C in nonleukemic lymphocytes in vitro and leukemia L1210 cells in vivo but did not influence ara-C anabolism in the other cell types. "
06/01/1983 - "Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine."
05/15/1989 - "Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia."
03/04/1977 - "Three of these selected compounds, pyrazofurin (pyrazomycin), ribavirin (Virazole), and 9-beta-D-arabinofuranosyladenine (ara-A), produced a significant (50%-100%) inhibition of virus-induced splenomegaly development in mice, whereas the other two candidate inhibitors, 3-deazauridine (deazaUR) and rifamycin SV, the other two candidate inhibitors, 3-deazauridine (deazaUR) and rifamycin SV, failed to demonstrate any in vivo activity in this 21-day leukemogenesis assay. "
|5.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)